- Home
- AUTL vs EU Comparison
AUTL vs EU Comparison
Compare AUTL & EU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUTL | EU |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Other Metals and Minerals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.2M | 361.2M |
| IPO Year | 2025 | 2011 |
Fundamental Metrics
Financial Performance| Metric | AUTL | EU |
|---|---|---|
| Price | $1.86 | $1.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $8.50 | $4.00 |
| AVG Volume (30 Days) | 1.7M | ★ 2.7M |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.76 |
| EPS | N/A | ★ 0.03 |
| Revenue | $10,120,000.00 | ★ $43,155,000.00 |
| Revenue This Year | $80.32 | $212.11 |
| Revenue Next Year | $53.96 | $29.88 |
| P/E Ratio | ★ N/A | $53.33 |
| Revenue Growth | ★ 496.00 | N/A |
| 52 Week Low | $1.18 | $1.34 |
| 52 Week High | $2.70 | $4.19 |
Technical Indicators
Market Signals| Indicator | AUTL | EU |
|---|---|---|
| Relative Strength Index (RSI) | 63.63 | 48.73 |
| Support Level | $1.27 | $1.34 |
| Resistance Level | $1.98 | $2.17 |
| Average True Range (ATR) | 0.14 | 0.10 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 83.65 | 90.00 |
Price Performance
Historical ComparisonAbout AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
About EU enCore Energy Corp.
enCore Energy Corp together with its subsidiary, is principally engaged in the acquisition, exploration, development and extraction of uranium resource properties in the United States. The Company is focused on the extraction of domestic uranium in the United States. The Company utilizes the In-Situ Recovery technology (ISR) to provide necessary fuel for the generation of clean, reliable, and carbon-free nuclear energy.